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The repair of bone defects and deficiencies due to trauma, cancer, birth defects, or aging are an 
interesting and important area of study for bone tissue engineering. The high demand for 
functional bone grafts has led to the search for artificial bone substitutes. Traditionally, non-
resorbable, inert metals and other rigid materials have been implemented for repairing bone 
defects [1-3]. However, these rigid materials do not allow for the appropriate and natural 
distribution of stresses and may lead to stress shielding [4]. Stress shielding is defined as the loss 
of bone density, and therefore strength, as a result of the removal of normal stress conditions on 
the bone caused by the presence of the implant [5]. Bone tissue engineering is the area of study 
which seeks to overcome the disadvantages and limitations of current approaches for bone repair 
by using regeneration-based methods combining biomaterials, cells, and growth factors [6].  
The following biomaterials are commonly used for bone tissue engineering applications: 
polymers, ceramics, bioactive glass, composites of polymers and ceramics, and resorbable 
metals. Some polymers used for repairing bone defects include: poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA), poly(caprolactone) (PCL), poly(propylene fumurate) (PPF), 
hyaluronic acid, chitosan, collagen, etc. [7]. Bioceramics frequently used for bone tissue 
engineering are hydroxyapatite (HA), calcium phosphate, and bioactive glasses containing 
silicate, calcium, phosphorus and sodium, and other bioactive inorganic materials [8]. The 
original bioactive glass is known as Bioglass 45S5 and contains 45% wt % SiO2, 24.5% wt % 
Na2O, 24.5 wt % CaO, and 6 wt % P2O5. [8]. Other bioactive glasses studied over the years 
contain elements such as fluorine, magnesium, strontium, iron, and others. In addition, many 
composites of polymers and bioactive glasses or ceramics have been attempted. [9].  
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Metals and metal alloys have also been commonly used as bone grafts. Some of the most 
used metals include stainless steel, vitallium, tantalum, and titanium [44]. Metals are useful in 
that they can be shaped, made porous, or used as coatings [45]. The porous structures allow for 
rapid ingrowth in bone grafts [45]. The main downside to using metals for bone grafts is that 
they will remain in the recipient and, as a result, may lead to the phenomenon of stress shielding 
[4]. 
Of the polymers and other materials listed above, PPF will be explored for its 
biodegradable, resorbable, and photocrosslinkable capabilities [10-16]. It has the ability to be 3D 
printed as a porous structure using ultra-violet (UV) light, photoinitiators such as Irgacure 819 
(BAPO), Irgacure 784, and light-absorber 2- Hydroxy-4-methoxybenzophenone (HMB), etc [13, 
15-17]. In addition, PPF, when crosslinked, exhibits advantageous properties of good mechanical 
strength and biocompatibility [13, 15-17]. Material biocompatibility and suitability for cell 
attachment, proliferation, and differentiation is of the utmost importance because cell death 
occurs in cytotoxic environments [18].  
Bone marrow derived human mesenchymal stem cells (BM-hMSCs) are the most 
commonly used cells for bone tissue engineering applications. They are one of the most 
favorable progenitor cells because of their immunomodulatory potential upon implantation into 
the body [19-22]. BM-hMSCs are expected to present very low to medium amounts of human 
leukocyte antigens (HLA, aka MHC class II antigens) so that they are not recognized as foreign 
cells and therefore, are not rejected by the recipient. BM-hMSCs ability to evade the host 
immune system allows them to modulate the surrounding environment and be useful as 
allogeneic cell sources for human application until these stem cells have matured into osteocytes 
[20]. Allogenic therapeutic approaches use tissues from non-identical people instead of tissues or 
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even proteins from one part of the body to another in the same individual [43]. Allografts allow 
the recipient individual can receive a bone graft without needing to take tissue or cells from 
another part of their body [43]. For this reason, the ideal application is to differentiate BM-
hMSCs to osteoblasts but not all the way to mature osteocytes, which would present HLAs. This 
allows cell seeded scaffolds to be implanted into the recipient’s body with little risk of rejection. 
Other cell types that have been studied for bone tissue engineering applications include 
fibroblasts, adipose derived MSCs, muscle derived MSCs, pluripotent MSCs, embryonic MSCs, 
and induced pluripotent MSCs. However, these cell types present high levels of cell surface 
antigens and thus lack the ability to evade the host immune system. Due to their lack of cell 
surface antigens and for their ease of proliferation and differentiation into osteoblasts, BM-
hMSCs have become the most commonly used cell type for bone tissue engineering. 
The use of bioactive molecules such as growth and differentiation factors, adhesion 
peptides, and osteotrophic drugs [23] has been explored at length regarding bone tissue 
engineering and regenerative medicine in general. The in vivo environment of skeletal formation 
is rich in molecules that stimulate cell adhesion, proliferation, migration, differentiation, 
osteogenesis, and vascularization.  Growth factors can be introduced at different times to induce 
desired outcomes such as proliferation and differentiation. For example, proliferation can be 
induced using one growth factor regime and then, differentiation of the cells can be caused by 
switching to a different growth factor regime. Growth factors commonly used for proliferation of 
BM-hMSCs include Fibroblast Growth Factor (FGF), Platelet-Derived Growth Factor (PDGF-b), 
Epidermal Growth Factor (EGF), and Vascular Endothelial Growth Factor (VEGF) [24-27]. 
Commonly used growth factors for osteogenic differentiation of BM-hMSCs include bone 
morphogenetic protein (BMP)-2, BMP-4, BMP-6, BMP-7, and other growth differentiation 
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factors (GDFs) [28-36]. Different methods have been used for introducing growth factors, 
including introduction to the cell environment via solubilization of growth factors in the cell 
culture medium. Additionally, growth factors should only be used at the in vitro level because in 
vivo exposure to growth factors can lead to unfavorable, dangerous outcomes such as 
malignancy, pain, unwanted differentiation, and teratogenicity [37, 38]. Prior studies that 
introduced BMPs in vivo have demonstrated unfavorable outcomes, such as uncontrolled bone 
formation [37]. 
Commercial media are available for the proliferation and differentiation of MSCs into 
osteoblasts through companies such as Lonza, RoosterBio, OH-Alive, and many others. 
However, such media are expensive and the exact compositions are proprietary and therefore 
unknown to the user. Therefore, development of a defined media which acts as effectively as the 
commercial media for bone tissue engineering applications would be beneficial to future work, 
especially clinical trials, because of FDA requirements that tightly monitor and control the use of 
growth factors and other bioactive molecules. 
We hypothesize that proliferation and differentiation can be achieved through the 
combination of growth factors and a suitable biocompatible material. This environment will 
allow BM-hMSCs to coat PPF scaffolds and subsequently secrete sufficient bone ECM for bone 
tissue engineering applications. Additionally, we hypothesize that the growth factor regime will 
be effective in achieving bone ECM on both 2D thin film scaffolds and 3D porous scaffolds. 
Scaffolds covered in bone ECM can act as artificial bone tissue engineered grafts because the 
host bone tissue can recognize the graft, leading to bone regeneration. We aim to optimize 
dosage of growth factors for coating PPF biomaterials with bone ECM. Our growth factor doses 
were chosen based on a careful literature search. However, an optimum dose has yet to be 
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determined and reported in literature. The following paper will discuss the results of different 
growth factor doses and osteogenic factors for proliferation and osteoblastic differentiation of 
BM-hMSCs. An optimum dose has been determined as a result of the findings of this work. We 
also hypothesize that our growth factor dose will work as well or better than commercially 
available media. Finally, the smooth translation of 2D to 3D results will be shown through 
replication of the optimized growth factor regimens on 3D printed, porous scaffolds.  
Primary Aims of Project 
The following thesis has three main objectives: 
1) Determine the appropriate growth factor regimen and doses for proliferation and 
differentiation of BM-hMSCs. 
Prior to beginning the study, careful review of the literature was necessary to determine which 
growth factors to use and what dosages to try. When looking at growth factors, the most 
important characteristics were induction of proliferation and osteogenic differentiation of BM-
hMSCs, safety/ controllability, dosage, and cost. Additionally, previous work with FGF, PDGF, 
and BMP-7 completed by the Osteo Engineering Lab contributed to the determination of the 
regimens.   
2) Achieve a mineralized, bone ECM layer on 2D thin film scaffolds using determined 
growth factor regimens. 
2D thin films with an area of 1 cm2 are very simple scaffold structures. Achievement of a 
mineralized, bone ECM layer on the 2D thin films was necessary prior to attempting to do the 
same on complex, 3D, porous scaffold geometry. Additionally, methods of analysis are typically 
easier to perform on the thin film scaffolds. Therefore, we first attempted the study on thin film 
scaffolds for their simplicity in fabrication, cell culturing, and analysis. 
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3) Validate the results from the 2D thin film scaffolds on 3D scaffold geometry. 
Lastly, it is important to show that the 2D thin film scaffold results could be replicated on 3D, 
porous scaffolds. This is specifically important because bone implants will ultimately be 3D and 
porous. Showing that an ECM layer can be achieved throughout a 3D scaffold shows that our 
growth factor regime and technique is not limited by structure type. Additionally, future work 
will aim to replicate the outcomes on abnormal or irregularly shaped implants. This is especially 
important because the current goal of the Osteo Engineering Lab is to create patient-specific 
bone tissue engineered implants. Therefore, ensuring that we can achieve an ECM layer on any 
scaffold is a must for future projects. 
Materials and Methods 
Materials 
hMSC (MSC-001, RoosterBio Inc., Frederick, MD), RoosterBio hMSC Differentiation Basal 
Medium (KT-004, RoosterBio Inc., Frederick, MD), LIVE/DEAD® Viability/Cytotoxicity Kit, 
for mammalian cells (Life Technologies, Grand Island, NY, USA),  0.25% Trypsin-EDTA (Life 
Technologies, Grand Island, NY, USA), MTT reagent (Sigma-Aldrich, St. Louis, MO, USA), 
DMSO (VWR, Radnor, PA, USA), PBS (Life Technologies, Grand Island, NY, USA), Acetone 
(VWR, Radnor, PA, USA), Ethanol (Fisher Scientific, Pittsburgh, PA, USA), toluidine blue 
(Sigma-Aldrich, St. Louis, MO, USA), FGF, PDGF-BB and EGF (PeproTech, Rocky Hill, NJ, 
USA), 2-Hydroxy-4-methoxybenzophenone (Sigma-Aldrich, St. Louis, MO, USA), Irgacure 784 
(BASF, Florham Park, NJ, USA), Irgacure 819 (BASF, Florham Park, NJ, USA), Sodium 
tetraborate (Sigma-Aldrich, St. Louis, MO, USA), Formaldehyde solution (Sigma-Aldrich, St. 
Louis, MO, USA), Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA), Bovine Serum Albumin 
(Life technologies, Grand Island, NY, USA), Alizarin Red S (Sigma-Aldrich, St. Louis, MO, 
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USA), Cetylpyridinium Chloride (Sigma-Aldrich, St. Louis, MO, USA), Fast Violet B (Sigma-
Aldrich, St. Louis, MO, USA), p-nitrophenol phosphate tablets (Sigma-Aldrich, St. Louis, MO, 
USA), Mayer’s Hematoxylin Solution (Sigma-Aldrich, St. Louis, MO, USA), Napthol AS-MX 
Phosphate Alkaline Solution (Sigma-Aldrich, St. Louis, MO, USA), Sodium phosphate 
monobasic monohydrate (Sigma-Aldrich, St. Louis, MO, USA), Sodium phosphate dibasic 
heptahydrate (Sigma-Aldrich, St. Louis, MO, USA), Ammonium Hydroxide (Sigma-Aldrich, St. 
Louis, MO, USA), Citrate Solution (Sigma-Aldrich, St. Louis, MO, USA) 
Frequently Utilized Techniques 
I. Washing/ Sterilization Methods for PPF scaffolds 
A simple washing and sterilization technique was developed to ensure that the thin film coupons 
and 3D porous scaffolds were prepared for cell attachment. The washing was performed to clean 
the scaffolds from debris and remove any remaining uncured resin. The sterilization was 
performed to give a sterile environment for the cells. The wash and sterilization consisted of the 
following steps (Note: all PBS is at the 1X concentration):  
Wash 
1. Wash the PPF thin films with PBS for 5 minutes. 
2. Aspirate the PBS, and replace with 70% acetone for 25 minutes. 
3. Aspirate the 70% acetone and replace with PBS for 5 minutes. Perform two additional 
PBS washes for 5 minutes. 
4. Aspirate the PBS, and replace with 70% acetone for 15 minutes. 
5. Aspirate the 70% acetone and replace with PBS for 5 minutes. Perform two additional 
PBS washes for 5 minutes. 




7. Autoclave on liquid cycle for sterilization. 
8. Aspirate the PBS. 
9. Place the PPF thin films in the well plate and incubate in FBS for 12 hours.  
After completion of the wash, sterilization, and FBS incubation, the scaffolds are ready for cell 
seeding. The wash steps ensure there is no uncross-linked PPF on the thin film surface and FBS 
incubation ensures that the scaffolds will be best suited for cell attachment and proliferation. 
II. Cell Culture 
BM-hMSCs were obtained at passage # 3 (P3) from RoosterBio and were expanded using 
RoosterBio basal medium and were seeded at passage # 5 (P5) on 1x1 cm2 PPF thin films. The 
cells were seeded by passage #5 to avoid the chance of any genetic drift or other variations 
which may occur at high passage numbers. The cells were seeded at a density of 2.5x104 
cells/cm2. For the proliferation study, RoosterBio basal medium was supplemented with FGF, 
PDGF-BB and EGF at 1X concentration (5 ng/mL, 40 ng/mL and 20 ng/mL, respectively) or at 
10X concentration (50 ng/mL, 400 ng/mL and 200 ng/mL, respectively). For differentiation, 
RoosterBio basal medium supplemented with the following osteogenic substances: 
dexamethasone (10-7), β-glycerophosphate (10mM), and ascorbic acid (50 µg/ml) was 
additionally supplemented with BMP-4, BMP-6, or BMP-7 at 1X concentration (50 ng/ml, 50 
ng/ml and 27 ng/ml, respectively) or at 10X concentration (500 ng/ml, 500 ng/ml, and 270 
ng/ml, respectively). These values are tabulated with references in Table 1. The doses were 
chosen based on information in literature and cost. 
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III. MTT assay 
MTT assay is used to determine cell proliferation quantitatively. A standard plot is first prepared 
so that absorbance values (A.U) can be correlated and the number of cells/group/time point can 
be determined. The thin films coated with cells for MTT assay were first washed in PBS. These 
were further incubated in 1 ml plain media containing 5 mg/ml MTT dye and incubated for 4 
hours in CO2 incubator under humidified (>95%) conditions in the presence 5% CO2 at 37°C 
temperature. After incubation, the well plate was removed from the incubator and MTT reagent 
was aspirated out. To these well, 1 ml dimethyl sulfoxide (DMSO) was added to solubilize the 
formazan crystals. The purple color generated was read spectrophotometrically at 405 nm 
wavelength. 
IV. SEM analysis 
SEM imaging was performed for visualization of cell coating, distribution, and proliferation on 
the scaffold surface. The samples for SEM analysis were first washed in PBS and then fixed in 
1% glutaraldehyde for 30 mins. Thereafter, these were treated with OsO4 for enhancing the 
contrast of the fixed cells. Further, samples were sequentially treated with graded ethanol series 
from 50% to 100%. Samples were then dried in critical point dryer (Pelco) and followed by 
sputter coating in gold plasma (Cressington 108 Sputter coater). Once the samples were gold 
coated, they were viewed via scanning electron microscope (FEI Nova NanoSEM 400) under 
following settings: high voltage = 5kV, spot size = 3 and working distance = 6-7 mm. 
V. Toluidine blue assay  
Toluidine blue staining was used as a qualitative analysis method for cell proliferation. The main 
purpose was to confirm the trends observed during the MTT assay. Cells were washed in 1X 
PBS for 5 mins then fixed in 3.7% formaldehyde solution in 1X PBS for 10 mins at room 
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temperature. Samples were washed with PBS then 0.1% Triton X-100 in 1X PBS for 5 mins in 
humidified conditions. The samples were washed again in 1X PBS before being incubated in 1% 
Bovine Serum Albumin (BSA) for 30 mins at room temperature. The samples were then washed 
again for a final time in 1X PBS. A 1% Toluidine Blue and 1% sodium tetraborate solution was 
made in distilled water (w/v%). The solution was mixed using a magnetic stir rod and plate and 
filtered using filter paper and filter tip syringe. Once the solution was made, a few drops were 
added to the fixed cells in the well plate. The well plate was then placed into a 50°C oven until 
the stain began to dry in the well plate. Several rinses of distilled water was used to remove any 
solution from the sample. After distilled water washes, the samples were then rinsed first with 
95% ethanol and then with 100% ethanol. The samples could be viewed either macroscopically 
or microscopically by qualitatively looking at the blue cells on the sample.  
VI. Qualitative ALP Staining 
Proliferating osteoblasts are known to produce alkaline phosphatase enzyme. As a result, these 
levels can be used to track the differentiation of hMSCs to osteoblasts and the proliferation of 
these osteoblasts. The ALP enzyme production of each of the groups was determined 
quantitatively by absorbance values at 405 nm. Qualitative ALP staining was performed to 
confirm results found in the ALP assay. The ALP staining samples were first fixed using a citrate 
buffered acetone solution. A diluted diazonium salt solution was created by dissolving a Fast 
Violet B capsule in distilled water. The alkaline dye solution was made by combining the dilute 
diazonium salt solution with Napthol AS-MX Phosphate Alkaline Solution (4% vol/vol). The 
samples were incubated in alkaline dye solution at room temperature for 30 minutes in the dark. 
Next, the samples were rinsed with deionized water for 2 min and then they were placed in 
Mayer’s Hematoxylin Solution for 10 minutes. They were viewed microscopically. 
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VII. Quantitative ALP Assay 
Quantitative ALP assay was performed to determine the relative amount of proliferating 
osteoblasts present on the scaffolds. One tablet of p-nitrophenol phosphate (pNPP) and one tablet 
of Tris buffer was dissolved in 20ml distilled water (20 ml). After the samples were incubated in 
alkaline phosphate stain, the stain was removed and the samples were washed thoroughly. pNPP 
substrate solution was added to each sample and they were incubated in the dark at room 
temperature for 30 minutes. After the incubation, the plate was read at 405 nm using a multi-well 
plate reader. 
VIII. Alizarin Red S Staining 
Alizarin Red S assay and staining can be used to determine bone mineralization because of the 
orange-red staining of calcium based mineral deposits/hydroxyapatite crystals. These crystal 
form as a result of osteoblastic activity during the later phase of osteoblast maturation. The 
media from the alizarin red S samples was removed and the samples were washed three times in 
1X PBS. The cells were fixed using cold 70% ethanol for 1 hour and allowed to air dry. A 0.5% 
ammonium hydroxide solution was prepared by diluting a 30% stock ammonium hydroxide 
solution in distilled water. The 40mM alizarin red S staining solution was created by dissolving 
powdered alizarin red S in distilled water and the pH was adjusted to 4.1-4.3 using 0.5% 
ammonium hydroxide. The samples were stained using alizarin red S for 1 hour at room 
temperature. The samples were then rinsed three times with distilled water and were imaged 
microscopically.  
IX. Alizarin Red S Assay 
0.1M Sodium Phosphate buffer was made from stock solutions of 1M monobasic 
NaH2PO4•H2O and 1M dibasic Na2HPO4 in distilled water. 10% cetylpyridinium solution 
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(wt/vol) was made by dissolving solid cetylpyridinium in 0.1M Sodium Phosphate Buffer, pH 
7.0. The alizarin red S staining samples were de-stained in 10% cetylpyridinium and the 
absorbance readings were collected at 562 nm using a multi-well plate reader.  
Experiment Methods – Two Dimensional Study 
I. Fabrication of Thin Film Two-Dimensional Scaffolds 
PPF was synthesized in the laboratory of Dr. Matt Becker with financial support from an AFRIM 
grant (W81XWH-14-2-0004). 3:1 PPF:DEF resin was synthesized. The resin was then diluted 
1:1 with diethyl fumarate (DEF) which is a dimer with a carbon to carbon double bond, so it can 
participate in the cross-linking network. Dissolving the PPF in DEF helps to reduce the viscosity 
of the resin so it can flow properly during 3D printing. The following photo-initiators and dyes 
were then added to the resin mixture to create an optimal photo-cross-linking environment: 
Irgacure 819/BAPO (0.7% w/w% with 1:1 PPF:DEF), Oxybenzone/2-Hydroxy-4-
methoxybenzophenone (0.4% w/w%) and Irgacure 784 (0.3% w/w%). Once all photo-initiators 
and dyes were mixed adequately into the resin, thin films were cast by placing resin (~6-7 drops) 
in between two glass microscope slides. The slides were then placed into a UV box for 30 mins 
to promote enough cross-linking to cut the samples into 1x1 cm2 squares. The samples were then 
placed back into the UV box for 7.5 hours to ensure all cross-linking has occurred. The structure 
of cross-linked PPF can be found in Figure 1. Once fully cross-linked, samples were washed and 
sterilized as described above. 
II. Preliminary Study: Cytotoxicity 
The cytotoxicity of the PPF thin films was analyzed using a live-dead assay in two ways: 1) by 
placing thin films on a BM-hMSC cell monolayer, and, 2) by seeding cells onto the thin films at 
a density of 2.5x104 cells/cm2. The cells in both the cases were first washed with PBS, thereafter, 
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live-dead stain was added at a concentration of 4 μM of calcein AM and 2 μM of ethidium 
homodimer (EthD) in PBS. These were incubated for 30 min at room temperature under dark 
conditions. After incubation, the live-dead stain was removed and ~ 20 µl PBS was added to 
each well in order to prevent drying during image procurement. 
A cytotoxicity analysis with live-dead staining was performed to validate that the cured 
resin was biocompatible and suitable for cell proliferation and growth. Cells that were stained 
green were living and cells stained red were dead. Cells were seeded onto PPF scaffolds and 
observed using Bright field and fluorescence microscopy techniques. The microscopy images 
included in Figure 3 demonstrate viable cell attachment and growth which confirms the absence 
of cytotoxicity in the PPF scaffolds. 
III. Preliminary Study: Cell Seeding Density 
Prior to beginning the study, the cell seeding density was determined through a preliminary cell 
seeding density study. The study aimed to determine the best cell seeding density which 
uniformly coated the scaffold and allowed for cells to have adequate room for proliferation. Cell 
seeding density was determined by seeding cells at different densities onto PPF scaffolds and 
observing the cells under microscopy for uniform coating and low confluence. The cells were 
seeded at densities of 10,000, 25,000, 50,000, 100,000, and 200,000 cells/ml on thin films (n=3) 
in ultra-low attachment 24-well plates. The cells were incubated and allowed to attach for four 
hours. After the 4 hour incubation, bright field imaging was performed using Olympus CKX41 
microscope (Olympus, Center Valley, PA) connected with a 12.8 MP digital camera.   
IV. Growth Factor Literature Review for ECM Study 
In order to determine the growth factors for proliferation and differentiation and respective 
doses, a literature review was undertaken. Previous work in the lab was referenced as well. After 
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careful review of the literature and previous work in the lab, we determined that FGF, PDGF, 
and EGF would be explored for their proliferation capabilities and that BMP-4, BMP-6, and 
BMP-7 would be explored for their differentiation capabilities. From the literature, the 1X doses 
were determined and tabulated in Table 1. The 10X dose was designed so that any potential 
difference between dose groups would be seen in the results if a difference existed.  
Table 1: Growth factor dose (1X and 10X) for proliferation and differentiation factors. The doses 
were determined by references given. 
 
V. Extracellular Matrix (ECM) Study 
The ECM study was performed with the primary aim of achieving an ECM layer on PPF scaffolds. 
An ECM layer prior to implantation allows for the scaffold to mimic bone upon implantation into 
the patient. In order to achieve an ECM layer, four experimental groups were studied for the 
analysis of cell proliferation, i.e., 1) 1X dose of FGF-2, PDGF-BB, EGF (E1X), 2) 10X dose of 
FGF-2, PDGF-BB, EGF (E10X), 1X dose of FGF-2, PDGF-BB (NE1X), and, 10X dose of FGF-
2 and PDGF-BB (NE10X) in hMSC Differentiation Basal Medium from RoosterBio Inc. Here, 
‘E’ stands for group containing EGF, and, ‘NE’ stands for the group not containing any EGF. The 
control media (CM) group for cell proliferation was hMSC Differentiation Basal Medium from 
RoosterBio Inc. that did not contain any growth factors. 
   Seven experimental groups were studied for cell differentiation, i.e., OM (osteogenic media 
containing 10-7 M dexamethasone, 10 mM β-glycerophosphate and 50 µg/ml ascorbic acid), 1X 
Growth Factor 1X Dose (ng/ml) 10X dose (ng/ml) Reference
FGF-2 5 50 39
PDGF-BB 40 400 40
EGF 20 200 41
Growth Factor 1X Dose (ng/ml) 10X dose (ng/ml) Reference
BMP-4 50 500 28,33
BMP-6 50 500 33





and 10X BMP-4 (1X and 10X dose of BMP-4 in osteogenic media), 1X and 10X BMP-6 (1X and 
10X dose of BMP-6 in osteogenic media), 1X and 10X BMP-7 (1X and 10X dose of BMP-7 in 
osteogenic media). The control group for differentiation study was the same as proliferation study. 
A schematic of the general work flow can be found in Figure 2.  
Experiment Methods – Three-Dimensional Study 
I. Fabrication of Three-Dimensional Porous Scaffolds 
The same resin chemistry as the 2D thin film scaffolds was used to print 3D cylindrical scaffolds 
of 6 mm diameter and 5 mm height with Schoen’s gyroid pore geometry. Other features include 
the strut size of 187.5 µm, pore size of 625 µm, surface area of 342.27 mm2 and volume of 17.77 
mm3. A computer aided design (CAD) file of these features was created using SolidWorks 
software (Dassault Systèmes, Waltham, MA). Further, this CAD file was 3D printed by using an 
EnvisionTEC Perfactory P3 3D printer (Dearborn, MI). To remove the cytotoxic uncured resin 
from the cross-linked polymer, washing was performed using 70% acetone and PBS. The 
samples were then sterilized in an autoclave and FBS incubated overnight before cell seeding. 
II. Replication of Two-Dimensional Findings on Three-Dimensional Scaffolds 
In order to show a smooth translation from 2D to 3D scaffolds, a 1X dose of EGF, FGF, and 
PDGF, as determined by the 2D study, was used to proliferate cells on the 3D porous scaffolds. 
The proliferation and coating will be observed by using SEM analysis at day 0 and day 7. Later, 
the full 2D study will be completed on the 3D scaffolds to show complete translation of the 




Results and Discussions – Two Dimensional Study 
Determination of Cell Seeding Density 
Cell seeding density was determined by seeding different densities of cells onto PPF thin film 
scaffolds and observing the cells under a microscope for cell coating and optimal density. After 
comparing the various cell seeding densities, it was determined that a cell seeding density of 
25,000 cells/ml was sufficient for uniform coating and produced a low density cell coat. A low 
density cell coating was desirable in order to limit cell usage and allow for proliferation of cells 
over time. In Figure 3, it is clear that 10,000 cells/ml (Figure 3A) did not produce a uniform cell 
coating and cell seeding densities of 50,000 cells/ml or higher (Figure 3C-E) led to high cell 
densities which would limit cell proliferation capabilities. Therefore, 25,000 cells/ml (Figure 3B) 
was used for the experiments. 
Analysis of Cell Proliferation 
I. MTT Assay 
As observed in Figure 4A, all groups show an increasing trend from day 1 to day 7. At day 7, the 
values of cell number for NE1X, NE10X, E1X, E10X, and, CM groups were 
91705.93±11965.23, 110208.75±4902.20, 116023.73±5164.69, 102212.32±16281.94 and, 
36976.08±4490.06, respectively. Among the groups of defined factors, E1X showed 
significantly higher proliferation than the NE1X and CM groups (p=0.001 and p=0.000, 
respectively). NE1X also showed significantly higher cell proliferation than the CM group 
(p=0.000). A similar trend was observed at the 10X dosage as well. However, there was not a 
significant difference between the results for the 1X and 10X doses. Therefore, it was determined 
that the 1X dosage would be appropriate and more cost effective for achieving cell proliferation 
on the thin film scaffolds. 
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II. Toluidine Blue Staining 
In Figure 4B, the cells represented by blue color show an increasing trend from day 1 to day 7 
for all groups. The CM (control) group showed very little proliferation between day 1 and day 7. 
The CM group did not have any growth factors added. The rest of the groups which contained 
growth factors, such as E1X, E10X, NE1X, and NE10X, showed much higher cell proliferation 
than the CM group. These results for cell proliferation, therefore, follow the trend observed in 
the MTT assay. 
III. SEM imaging and analysis 
Figure 5A shows that at day 0, the cell distribution was uniform on the surface of the thin film 
coupons for all growth factor groups. Based on visual observation of the cells at this time point, 
it was determined that round morphology of the cells suggested initial attachment. By day 7 in 
Figure 5B, all of the groups showed uniform cell spreading, coating, and distribution. At this 
time point, it appeared that the thin film scaffolds were completely coated with cells. Therefore, 
we chose the day 7 time point for switching the environment of the cells to osteogenic media for 
osteogenic differentiation. It is important to note the difference in appearance of the cells from 
growth factor containing groups and the CM (control) group. The CM group showed better cell 
spreading at both day 0 and day 7.  Perhaps there is a difference of cell behavior in the presence 
of growth factors. 
Analysis of hMSC differentiation 
I. Alkaline Phosphatase Assay and Stain 
In Figure 6A, all groups show an increasing trend from MSC to osteoblast from day 14 to day 21 
(day 0 to day 7 is cell proliferation). The average values at day 14 for BMP-4 1X, BMP-4 10X, 
BMP-6 1X, BMP-6 10X, BMP-7 1X, BMP-7 10X, OM and CM are 2.52±0.51, 3.23±0.10, 
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2.80±0.25, 3.22±0.11, 2.54±0.43, 1.45±0.34, 3.28±0.14, 0.76±0.30 A.U., respectively. While, the 
readings for the same sequence of groups at day 21 was as follows: 6.11±0.18, 6.49±0.10, 
6.50±0.09, 6.45±0.11, 5.96±0.19, 6.54±0.09, 6.39±0.11, 1.23±0.11 A.U., respectively. Statistical 
analysis at day 14 showed that the osteogenic media showed significantly higher values than any 
of than 1X doses of BMP-4 (p=.000), BMP-6 (p=.010) and BMP-7 (p=.000), along with, BMP-7 
10X (p=.000) and CM (p=.000). However, analysis at day 21 shows that osteogenic media only 
has significantly higher values than BMP-7 1X (p=.006) and CM (p=0.000). Additionally, the 
10X doses were found to be significantly higher (p<0.05) for all of the groups except for the 
BMP-6 group at day 21.  
 ALP Staining was performed to qualitatively confirm the trends observed in the ALP 
assay. The red color in and around the cells indicates the presence of ALP enzyme. As shown in 
Figure 6B, an increasing trend was observed from day 14 to day 21 for all of the groups. This 
observation matches the results found in the quantitative ALP assay. 
II. Alizarin Red S Assay and Stain for Bone Mineralization 
Figure 7A shows an increasing trend for bone mineralization for all growth factor groups from 
day 14 to day 21. The average values at day 14 for BMP-4 1X, BMP-4 10X, BMP-6 1X, BMP-6 
10X, BMP-7 1X, BMP-7 10X, OM and CM are 0.30±0.04, 0.35±0.04, 0.30±0.03, 0.31±0.05, 
0.36±0.06, 0.31±0.04, 0.25±0.02, 0.21±0.02 A.U., respectively. While, the readings for the same 
sequence of groups at day 21 was as follows: 0.37±0.06, 0.45±0.05, 0.49±0.06, 0.53±0.04, 
0.79±0.07, 0.75±0.05, 0.41±0.06, 0.26±0.05 A.U., respectively. In Figure 7A, the BMP-7 group 
showed a significantly higher level of mineralization at day 21 than all other groups (p<0.000), 
regardless of concentration. Also, it was found that BMP 7 1X and 10X did not differ much in 
effectiveness. Therefore, it was found that the BMP-7 1X dose would be sufficient and most cost 
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effective for inducing mineralization of osteoblastic cells formed during osteogenic 
differentiation of hMSCs on PPF polymer surfaces. These results were further confirmed by the 
observation of similar trends during the qualitative analysis of alizarin red S staining shown in 
Figure 6B. 
III. SEM Analysis for Cell Differentiation 
SEM imaging and analysis was performed at day 21 for each group in order to visualize the 
mineralized crystal formation on the PPF thin film scaffolds. The images can be found in Figure 
8. The images for each group showed formation of crystal like structures represented by whitish 
dots on cell layers suggesting mineralization of the osteoblast. All of the groups showed uniform 
distribution of crystals, except the CM group. The observed crystals are closely linked with ECM 
thread, which further suggests the presence of hydroxyapatite crystals formed at the nucleation 
sites of collagenous matrix typically found during osteogenic maturation and mineralization of 
osteoblasts.  
Results and Discussions - Three-Dimensional Study 
Analysis of hMSC Proliferation and Coating 
I. SEM Analysis for Cell Proliferation and Coating 
A critical step for our research efforts is to validate the feasibility of the translation of results 
obtained from 2D thin film surface studies to 3D printed scaffolds. The first step for assessing the 
feasibility is the uniform seeding of cells on the 3D scaffold surface along with proliferation of 
those cells at a later time point. Therefore, we assessed this phenomenon via SEM analysis at day 
0 and day 7 (Fig. 8).  As shown in Fig. 8A and B, at day 0, the BM-hMSCs initially show a rounded 
morphology with initiation of spreading at some places. Whereas, at later time point of day 7, all 




The present study provides an optimized regimen of growth factors for the proliferation and 
differentiation of BM-hMSCs on the surface of 2D and 3D PPF scaffolds. It suggests the suitability 
of PPF polymer for the development of artificial bone tissue engineered biomaterials containing a 
layer of extracellular matrix on their surface for the treatment of bone defects. Achieving an ECM 




Further work will need to be completed for the three-dimensional study. Although cell 
proliferation and coating was achieved on the 3D polymer scaffold, as shown in Figure 9A-D, a 
complete duplicate study modeling the two-dimensional study will need completed to confirm 
our results quantitatively. A study was previously attempted but contamination issues led to poor 
data and bad results. Therefore, redoing the study will be a must for our future work. 
Defined Media Study 
The defined media study was begun to ensure that our defined media and growth factor doses 
were as efficient and effective as undefined, commercial media in producing BM-hMSC 
proliferation and differentiation to osteoblast. The main purpose for having a defined media is 
for future aspirations of clinical trials in which defined components will be necessary for 
receiving permission to perform the trial. For this study, RoosterBio media with osteogenic 
factors of dexamethasone (10-7), β-glycerophosphate (10mM), and ascorbic acid (50 µg/ml) 
along with defined growth factors were evaluated for osteogenic differentiation. The defined 
growth factors for proliferation as determined by the present study are the following: FGF (5 
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ng/ml), PDGF-b (40 ng/ml), and EGF (20 ng/ml). The defined growth factor added for 
differentiation is BMP-7 (27 ng/ml). These proliferation and differentiation media will be 
compared to Lonza proliferation and osteogenic differentiation media and OH-Alive 4 step 
media system for osteogenic differentiation. In order to test the different media, cells will be 
seeded on 2D thin film coupons as determined by the present study. The study will be run for 
one week in proliferation media in accordance with our 2D thin film results. Some samples will 
be pulled to study the efficiency of the media to facilitate cell proliferation by using MTT, SEM, 
and Toluidine Blue. The culturing environment will then be changed to differentiation media 
suitable for cell differentiation into osteoblast for the remaining samples and the study is 
concluded at two weeks, i.e. 14 days. The differentiation and mineralization of the cells will be 
analyzed by ALP stain and assay and Alizarin Red S stain and assay. SEM images will also be 
taken again for additional qualitative assessment. The results for each media type will be 
compared to each other to determine the effectiveness of each media type for the desired 
proliferation and differentiation of the cells. 
Other Work 
As a result of our findings on 2D thin film coupons and 3D porous, cylindrical scaffolds, it 
would be appropriate and interesting to continue research in bioactive molecules as well as 
seeding methods for scaffolds of different sizes and shapes. Future work will look to develop 
seeding methods and defined factors which can be repeated on scaffolds for patient-specific 
implants. This will be achieved by reproducing 3D study findings on 3D scaffolds of various 
shapes. It is extremely important to have a defined method since areas of trauma will be variable 
amongst patients. Also, the incorporation of ligands (as bioactive molecules) with the surface of 
the polymer will be explored regarding cell attachment, proliferation, and differentiation. 
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 In addition, several animal studies will be completed to advance our work towards 
clinical trials. Animal models will include mice, rats, and larger animals such as dogs. 
Previously, a SCID mouse study was completed to show vascularization could be achieved 
through the pores of the scaffold. Results showed that vascularization could be achieved on 
scaffolds, imbedded with novel spheroids of HUVECs and HMSCs, implanted subcutaneously. 
Although this work is not presented in this document, it contributes to our desires to pursue other 
animal studies. One possible study will involve implanting 3D porous scaffolds into rats for the 
purpose of repairing segmental femur defects. Another potential future study is a dog mandible 
study. In such a study, a PPF mandibular implant will be pre-seeded using in-house techniques 
that produce proliferating osteoblasts prior to implantation, with the direction that the cells will 
further mature into bone. These animal model studies, hopefully, will aid in our pursuit to gain 
approval for a human clinical study in the future. The aim is to provide a defined, repeatable 
method for developing successful, patient specific bone grafts which perform with less 
limitations than traditional bone grafts. 
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Figure 1. Photo-crosslinked PPF through the carbon to carbon double bond. The repeating unit 




Figure 2. A schematic representation of the experiment plan for the ECM study for the 2D ECM 
study. Finally, the translation ECM layer deposition from 2D thin films to 3D printed scaffolds 
with gyroid pore geometry having open pore structure is shown as the final step for preparation 
of artificial PPF polymer based bone tissue engineered grafts.   
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Figure 3. Determination of optimum cell seeding density for the study of BM-hMSC 
proliferation on PPF polymer surface. The bright field microscope images of BM-hMSC seeded 
PPF thin films are shown at cell densities of 10,000, 25,000, 50,000, 100,000, and, 200,000 
cells/ml (A through D, respectively). The density of 25,000 cells/ml was chosen as initial cell 
density due to uniform and scattered distribution of cells (scale bar = 500m). Additionally, 
25,000 cells will allow for the proliferation of cells.   
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Figure 4. Study of cell proliferation in the presence of FGF-2, EGF and PDGF growth factors at 
1X and 10X doses. In 4A, the cell number determined by MTT assay shows a significantly 
(p**=0.001) higher cell proliferation in 1X EGF containing (E1X) group in comparison to the 
group without EGF (NE1X). Whereas, the control media (CM) depicts lowest cell proliferation. 
Figure 4B represents the qualitative analysis of these results through toluidine blue staining. All 
the groups show increasing trend of cell proliferation from day 1 and day 7 similar to that of 




Figure 5. Scanning electron microscope image analysis of BM-hMSC proliferation. As shown in 
5A, all the growth factor containing groups (E1X, NE1X, E10X and NE10X) show similar initial 
attachment at day 0 with mostly rounded morphology. While, these cells spread uniformly and 
coat the polymer surface by day 7 as demonstrated in 5B. However, the CM group shows higher 
cell spreading at both the time points (magnification of all images = 250X).   
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Figure 6. Analysis of osteogenic differentiation through alkaline phosphatase (ALP) enzyme 
assay and staining. During ALP enzyme assay, shown in 6A, all the groups show increase in 
absorbance readings with increase in time day 14 to 21. OM group at day 14 time point shows 
significantly (p*≤0.05, p**≤0.01, p***≤0.001) higher values than all other groups except BMP-4 
10X and BMP-6 10X. While, at day 21, growth factor containing groups show a rapid increase in 
ALP production and OM group only shows statistically higher values than BMP-7 1X 
(p**≤0.01) and CM group (p***≤0.001). 6B depicts the ALP staining results for the same group 
types and the diffused red staining indicated the presence of enzyme. All the groups showed 





Figure 7. Study of osteogenic mineralization through alizarin red S assay and staining. As shown 
in 7A, BMP-7 1X group shows significantly (p*≤0.05, p**≤0.01, p***≤0.001) higher 
mineralization than all the other groups except BMP-4 10X group at day 14 time point. Whereas 
at day 21 BMP-7 (1X and 10X) group displays significantly higher mineralization than all other 
groups.  As observed in 7B, similar results were obtained during the staining studies for 





Figure 8. Scanning electron microscopy image analysis of mineralization. All the groups (except 
control) show extensive mineralization via presence of depicted hydroxyapatite-like crystals 
depicted by whitish dots associated with extracellular matrix threads. As expected, the CM group 
shows least mineralization (magnification of all images = 2000X).   
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Figure 9. Validation of 3D printed PPF scaffold seeding, spreading and coating via BM-hMSC 
cells. At day 0 time point, cells mostly show rounded morphology with uniform distribution at 
lower magnification (A), while, some cells did show initiation of spreading upon observation at 
higher magnification (B). On the other hand, at day 7 time point, all the cells show uniform 
spreading and coating at lower (C) and higher (D) magnifications. Magnification for images A 
and C = 250X, and, images B and D = 500X. 
